trending Market Intelligence /marketintelligence/en/news-insights/trending/Qc3BGzTsCh1rIVsFAwFOWg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Targovax plans private placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Targovax plans private placement

Norway-based Targovax ASA intends to raise gross proceeds of 175 million to 225 million Norwegian kroner in a private placement of new shares.

Targovax set the minimum subscription and allocation to the number of new shares equal to the aggregate subscription price of at least the kroner equivalent of €100,000. Two of the largest Targovax shareholders, HealthCap and Norwegian Radium Hospital Research Foundation, will subscribe for up to 25 million kroner and 5 million kroner, respectively.

The accelerated book building process to determine the subscription price started June 8 and will close June 9, unless extended or canceled by the company.

Targovax plans to use the net proceeds to finance five additional data read-outs from clinical trials through 2018 and selective CMC development in preparation for future pivotal clinical studies.